Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease
- PMID: 1768767
Discrepant increase in factor VIII: C and von Willebrand factor after DDAVP infusion in a patient with variant von Willebrand's disease
Abstract
We have studied a patient with von Willebrand's disease (vWd) whose von Willebrand factor (vWf) multimer patterns showed significant decreases of all but the major fast moving vWf multimer (promoter). Bleeding time (BT) was very prolonged, there was almost no ristocetin-induced platelet aggregation (RIPA) and vWf levels were very low. The factor VIII: C/vWf: Ag ratio appeared to be higher than normal because of the relatively increased concentration of factor VIII: C. The infusion of DDAVP normalized BT, improved RIPA and restored normal factor VIII: C levels, these effects lasted for 5 h even though only a slight increase of vWf: Ag and vWf: RCoF was observed. RIPA was completely inhibited by an anti-glycoprotein (GP) Ib monoclonal antibody that recognizes the ristocetin-induced vWf binding site. Plasma vWf multimer analysis revealed only slight increases of all components and an additional, more pronounced representation of vWf protomer. These data suggest that the patient has an abnormal vWf molecule characterized by a greater ability to carry factor VIII than would be expected from the vWf levels. Furthermore, since the vWf protomer was the only significant vWf component present both before and after DDAVP infusion we hypothesize that some of the haemostatic functions of the patient's vWf may depend on it.
Similar articles
-
Response of von Willebrand factor parameters to desmopressin in patients with type 1 and type 2 congenital von Willebrand disease: diagnostic and therapeutic implications.Semin Thromb Hemost. 2002 Apr;28(2):111-32. doi: 10.1055/s-2002-27814. Semin Thromb Hemost. 2002. PMID: 11992235 Clinical Trial.
-
A new variant of von Willebrand's disease (type I Padua): doublet-organized plasma von Willebrand factor oligomers in the presence of all size multimers.Haematologia (Budap). 1994;26(2):97-109. Haematologia (Budap). 1994. PMID: 7890268
-
Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.Clin Appl Thromb Hemost. 2007 Jan;13(1):14-34. doi: 10.1177/1076029606296399. Clin Appl Thromb Hemost. 2007. PMID: 17164493 Review.
-
DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.Blood Coagul Fibrinolysis. 1996 Jul;7(5):549-53. Blood Coagul Fibrinolysis. 1996. PMID: 8874865
-
Laboratory diagnosis and molecular classification of von Willebrand disease.Acta Haematol. 2009;121(2-3):71-84. doi: 10.1159/000214846. Epub 2009 Jun 8. Acta Haematol. 2009. PMID: 19506352 Review.
Cited by
-
DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.Blood. 2025 Apr 17;145(16):1814-1825. doi: 10.1182/blood.2024026804. Blood. 2025. PMID: 39854691 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous